Skip to main content
  • Poster presentation
  • Open access
  • Published:

Anaphylaxis during specific subcutaneous immunotherapy against ragweed allergen -- case record

Background

Recommended by Resolution of Immunotherapy, issued by EAACI, Specific immunotherapy (SIT) was established as a mainstream method of treating allergic diseases. SIT produces long term challenges. SIT team should be aware that at first injection of allergen, the immunotherapy may cause a long lasting reaction. Anaphylaxis during SIT is very rare, but it is possible. We've experienced anaphylaxis after four year of SIT, against ragweed allergen.

Methods

A fifty four year old female went into anaphylactic shock after four years of SIT against ragweed allergen. Before the start of SIT, complete diagnostic procedures had been performed. Intradermal skin tests were performed for standard pallet of contact, inhalation, and nutritional allergens. The female patient tested positive for Ragweed (high positive), fungi (aspergillum fumigates, altenaria), and milk. Total IgE was measured using Enzyme Linked Immunoassay (ELISA).

Result

After injection of the SIT maintenance dose (0.2 ml of second concentration of allergen, (product of authorized Immunologic Laboratory Production) against ragweed, anaphylaxis developed within five minutes. The first manifestation was itchy palms and itching of eyes, followed by a rash. A dose of 0.0005 gram epinephrine was administered subcutaneously immediately. After the epinephrine injection, an IV rout was established with 0.9 % saline infusion, 0.2 gram of hydrocortisone, and 0.020 gram of chloropiramin was administered intramuscularly. No bronchoobstruction developed. Patient displayed anxiety. After an hour of treatment, the symptoms of anaphylaxis subsided.

Conclusion

Anaphylaxis can develop as a complication of SIT with any possible manifestation. Treatment of anaphylaxis should start immediately after initial symptoms. The use of epinephrine is recommended.

Author information

Authors and Affiliations

Authors

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prnjavorac, B., Deljkić, A., Sinanović, A. et al. Anaphylaxis during specific subcutaneous immunotherapy against ragweed allergen -- case record. Clin Transl Allergy 4 (Suppl 3), P75 (2014). https://doi.org/10.1186/2045-7022-4-S3-P75

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/2045-7022-4-S3-P75

Keywords